FLGT - Fulgent Genetics to Announce Third Quarter 2022 Financial Results on Monday November 7 2022

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its third quarter 2022 financial results after the market closes on Monday November 7, 2022. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The call may be accessed through a live audio webcast on the Investor Relations section of the company’s website, http://ir.fulgentgenetics.com . An audio replay will be available at the same location.

About Fulgent Genetics

Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing, or NGS, with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated laboratory services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005803/en/

Investor Relations Contact:
The Blueshirt Group
Melanie Solomon, melanie@blueshirtgroup.com